Tempus AI, Inc. (NASDAQ:TEM) stock rose Monday after the company released preliminary fourth-quarter and full-year 2025 results on Sunday.
2025 Preliminary Results
For 2025, the company reported revenue of around $1.27 billion, reflecting about 83% year-over-year growth, including roughly 30% organic growth excluding Ambry.
By segment, Diagnostics revenue reached about $955 million, up roughly 111% year over year, led by oncology test volume growth of around 26% and hereditary testing growth of approximately 29%.
Also, Data and applications revenue totaled about $316 million, representing roughly 31% year-over-year growth, driven by an estimated 38% increase in Insights (data licensing).
Fourth-Quarter Results
Also, Tempus AI sees quarterly revenue of about $367 million, up 83% year over year, with Diagnostics revenue of roughly $266 million (+121% year over year) driven by oncology volume growth of about 29% and hereditary testing growth of approximately 23%.
Moreover, Data and applications revenue stood at $100 million, up …